Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03994081 · ClinicalTrials.gov registry record · NA

Mechanism of Action of tACS for the Treatment of MDD

A NA study of Major Depressive Disorder and MDD, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT03994081 is a NA study of Major Depressive Disorder and MDD that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 20 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03994081, a NA study of Major Depressive Disorder and MDD, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to use a specific type of non-invasive brain stimulation known as transcranial alternating current stimulation (tACS) to determine its effects on brain activity (measured with EEG) and mood in patients with Major Depressive Disorder (MDD).

Interventions

  • DEVICE tACS
  • DEVICE Sham tACS

Study Locations (1)

North Carolina

  • UNC at Vilcom Center - Chapel Hill

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2021-06-09
Est. Completion 2023-06-02
Phase NA

What the Registry Record Tells You About NCT03994081

The ClinicalTrials.gov registry entry for NCT03994081 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which tACS is the first listed.

NCT03994081 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT03994081 about?

NCT03994081 is a clinical study titled "Mechanism of Action of tACS for the Treatment of MDD". The purpose of this research study is to use a specific type of non-invasive brain stimulation known as transcranial alternating current stimulation (tACS) to determine its effects on brain activity (measured with EEG) and mood in patients with Major Depressive Disorder (MDD).

What is the current status of trial NCT03994081?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2021-06-09. Estimated completion is 2023-06-02.

What conditions does trial NCT03994081 study?

This clinical trial studies the following conditions: Major Depressive Disorder, MDD.

What interventions are being tested in trial NCT03994081?

The interventions under investigation include: tACS (DEVICE), Sham tACS (DEVICE).

Who is sponsoring clinical trial NCT03994081?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03994081 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.